文摘
In the search for new hypotensive agents some new aroxyalkyl or aroxyethoxyethyl derivatives of piperazine have been synthesized and evaluated for their pharmacological properties. Pharmacological tests included receptor binding assays toward adrenergic receptors α1, α2 and β1, additionally 5-HT1A, functional bioassay and in vivo evaluation of hypotensive activity as well as antidepressant-like potential. All the tested compounds exhibited α1-antagonistic properties, three of them possessed also hypotensive activity in rats. The most promising compound class="boldFont">3 1-[4-(2,6-dimethylphenoxy)butyl]-4-(2-methoxyphenyl)piperazine hydrochloride was a selective α1 receptor antagonist (Ki = 23.5 ± 1.3, α1/α2 = 15.77, pKB = 8.538 ± 0.109). It was active in all tested doses in vivo (1, 0.5, and 0.1 mg/kg) and it reduced blood pressure by 10–13% at the dose of 1 mg/kg (rats, i.v.). Compound class="boldFont">5 1-[2-(2,3-dimethylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine dihydrochloride exhibited the lowest dose for antidepressant-like activity 5 mg/kg b.w. (mice, i.p.) without influence on spontaneous activity (mice, i.p.).